Cargando…
Biosimilars: the process is the product. The example of recombinant streptokinase
BACKGROUND: Worldwide, streptokinase remains the most used thrombolytic agent for the treatment of myocardial infarction. Recombinant streptokinase, from E. coli, is increasingly used in developing countries as a biosimilar of native streptokinase; however, potency assignments relative to the WHO In...
Autores principales: | Thelwell, C, Longstaff, C |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BlackWell Publishing Ltd
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4241032/ https://www.ncbi.nlm.nih.gov/pubmed/24913658 http://dx.doi.org/10.1111/jth.12629 |
Ejemplares similares
-
Activity Regulation by Fibrinogen and Fibrin of Streptokinase from Streptococcus Pyogenes
por: Huish, Sian, et al.
Publicado: (2017) -
FcγRIIa - dependent platelet activation identified in COVID-19 vaccine-induced immune thrombotic thrombocytopenia-, heparin-induced thrombocytopenia, streptokinase- and anisoylated plasminogen-streptokinase activator complex-induced platelet activation
por: Abdelouahed, Mustapha, et al.
Publicado: (2023) -
Recombinant production of Streptococcus equisimilis streptokinase by Streptomyces lividans
por: Pimienta, Elsa, et al.
Publicado: (2007) -
Tenecteplase compared with streptokinase and heparin in the treatment of pulmonary embolism: an observational study
por: Agrawal, Ashish, et al.
Publicado: (2017) -
The chronergy of recombinant streptokinase thrombolysis in acute myocardial infarction
por: WANG, ZHONG-MING, et al.
Publicado: (2013)